AMP Capital Investors Ltd trimmed its position in Qiagen NV (NASDAQ:QGEN) by 39.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 62,990 shares of the company’s stock after selling 40,903 shares during the period. AMP Capital Investors Ltd’s holdings in Qiagen were worth $1,982,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership bought a new position in shares of Qiagen in the second quarter worth about $26,408,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Qiagen during the 2nd quarter valued at approximately $18,234,000. WINTON GROUP Ltd purchased a new position in Qiagen during the 2nd quarter valued at approximately $15,088,000. Atlanta Capital Management Co. L L C purchased a new position in Qiagen during the 2nd quarter valued at approximately $14,210,000. Finally, Vanguard Group Inc. grew its holdings in Qiagen by 7.0% during the 2nd quarter. Vanguard Group Inc. now owns 6,053,863 shares of the company’s stock valued at $202,986,000 after buying an additional 394,201 shares in the last quarter. 62.09% of the stock is currently owned by institutional investors and hedge funds.
Qiagen NV (NASDAQ QGEN) traded up $0.24 on Thursday, hitting $32.19. The stock had a trading volume of 774,037 shares, compared to its average volume of 991,175. The company has a market cap of $7,430.00, a price-to-earnings ratio of 82.54, a price-to-earnings-growth ratio of 1.80 and a beta of 1.10. The company has a current ratio of 5.33, a quick ratio of 4.78 and a debt-to-equity ratio of 0.68. Qiagen NV has a 52-week low of $27.51 and a 52-week high of $36.34.
Qiagen (NASDAQ:QGEN) last announced its earnings results on Monday, November 6th. The company reported $0.32 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.32. Qiagen had a return on equity of 11.36% and a net margin of 6.40%. The company had revenue of $364.00 million for the quarter, compared to analyst estimates of $363.42 million. During the same period in the prior year, the company posted $0.29 EPS. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. research analysts forecast that Qiagen NV will post 1.25 earnings per share for the current fiscal year.
A number of equities analysts have recently commented on QGEN shares. BidaskClub upgraded Qiagen from a “sell” rating to a “hold” rating in a report on Friday, January 5th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Qiagen in a report on Tuesday, November 7th. Cowen reiterated a “hold” rating and issued a $33.00 target price on shares of Qiagen in a report on Friday, November 3rd. Zacks Investment Research cut Qiagen from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Finally, Commerzbank reaffirmed a “buy” rating on shares of Qiagen in a research report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $34.63.
ILLEGAL ACTIVITY NOTICE: “AMP Capital Investors Ltd Has $1.98 Million Position in Qiagen NV (NASDAQ:QGEN)” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/11/qiagen-nv-qgen-holdings-reduced-by-amp-capital-investors-ltd.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.